Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278824 · ClinicalTrials.gov registry record · Phase 2
Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
A Phase 2 study, sponsored by ZARS Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT00278824 is a Phase 2 study that was terminated before completion, run by ZARS Pharma. The registered enrollment target is 109 participants.
The verdict
NCT00278824, a Phase 2 study, was terminated before completion, sponsored by ZARS Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the treatment of breakthrough pain in adult patients with moderate to severe non-malignant chronic pain. The open-label study arm will last up to 12 days. The double-blind arm will last up to 15 days. Eligible patients who complete the open-label arm will be allowed to enroll in the double-blind study arm.
Interventions
- DRUG Placebo Patch
- DRUG Matrix Transdermal Fentanyl/CHADD Drug Delivery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00278824
The ClinicalTrials.gov registry entry for NCT00278824 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Patch is the first listed.
NCT00278824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00278824 about?
NCT00278824 is a clinical study titled "Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain". A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the treatment of breakthrough pain in adult patients with moderate to severe non-malignant chronic pain. The open-label study arm wi...
What is the current status of trial NCT00278824?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2006-01. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00278824?
The interventions under investigation include: Placebo Patch (DRUG), Matrix Transdermal Fentanyl/CHADD Drug Delivery System (DRUG).
Who is sponsoring clinical trial NCT00278824?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.